CLOs on the Move

TFS HealthScience

www.tfscro.com

 
TFS was founded in 1996 and has grown to become a leading global mid-size clinical CRO focusing on small and mid-size life science customers. TFS employs more than 700 professionals throughout 21 countries and currently delivers clinical research services in more than 40 countries.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.tfscro.com
  • 212 Carnegie Center Suite 208
    Princeton, NJ USA 08540
  • Phone: 609.775.9500

Executives

Name Title Contact Details

Similar Companies

Carewell

Carewell is an e-commerce company that provides home health products with discreet packaging and 24/7 service. They aim to improve the lives of caregivers and their loved ones by offering proactive service, compelling content, and expert-vetted products.

Jack Gold Surgical Appliances

Jack Gold Surgical Appliances is a Randolph, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Crawford County Mental Health

Crawford County Mental Health Center is a community mental health center that provides mental health and substance abuse services to adults and children in Crawford County, Kansas.

winter resources

winter resources is a Grass Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.